These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 4027870)

  • 1. Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A Phase II study by the Illinois Cancer Council.
    Haid M; Khandekar JD; Christ M; Johnson CM; Miller SJ; Locker GY; Merrill JM; Reisel H; Hatfield A; Lanzotti V
    Cancer; 1985 Sep; 56(6):1311-5. PubMed ID: 4027870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response rate and toxicity with aziridinylbenzoquinone in patients with recurrent gliomas. A progress report.
    Tapazoglou E; Kish J; Ensley J; Al-Sarraf M
    Am J Clin Oncol; 1988 Aug; 11(4):474-8. PubMed ID: 3407628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors.
    Eagan RT; Dinapoli RP; Cascino TL; Scheithauer B; O'Neill BP; O'Fallon JR
    J Neurooncol; 1987; 5(4):309-14. PubMed ID: 3440875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
    Decker DA; Al Sarraf M; Kresge C; Austin D; Wilner HI
    J Neurooncol; 1985; 3(1):19-21. PubMed ID: 2987424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.
    Chamberlain MC; Prados MD; Silver P; Levin VA
    J Neurooncol; 1988 Dec; 6(4):319-23. PubMed ID: 3221259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary communication--treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ;NSC-182986).
    Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD
    Am J Clin Oncol; 1983 Oct; 6(5):577-8. PubMed ID: 6613923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of aziridinylbenzoquinone (NSC 182986).
    Bedikian AY; Bodey GP; Burgess MA; Freireich EJ
    Cancer Clin Trials; 1981; 4(4):459-63. PubMed ID: 7318128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma.
    Creagan ET; Schutt AJ; Ahmann DL; Green SJ
    Cancer Treat Rep; 1982 Dec; 66(12):2089-90. PubMed ID: 7139650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group Study.
    Taylor SA; McCracken JD; Eyre HJ; O'Bryan RM; Neilan BA
    J Neurooncol; 1985; 3(2):131-5. PubMed ID: 2993536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of 5-day continuous infusion aziridinylbenzoquinone (AZQ, diazaquone, NSC 182968).
    Sigman LM; Van Echo DA; Whitacre MY; Aisner J; Budman DA; Shulman P
    Am J Clin Oncol; 1986 Feb; 9(1):79-82. PubMed ID: 3953494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
    Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer and leukemia group B phase II non-small cell lung carcinoma trial: aziridinylbenzoquinone (AZQ).
    Carey RW; Comis RL; Anbar D; Kennedy BJ; Capizzi RL; Shulman P; Booth BW; Green M; Raich PC
    Cancer Treat Rep; 1983 Jan; 67(1):95-6. PubMed ID: 6616498
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of patients with recurrent primary brain tumors with AZQ.
    Schold SC; Friedman HS; Bjornsson TD; Falletta JM
    Neurology; 1984 May; 34(5):615-9. PubMed ID: 6538653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
    Feun LG; Yung WK; Leavens ME; Burgess MA; Obbens EA; Bedikian AY; Savaraj N; Stewart DJ; Benjamin RS; Fields WS
    J Neurooncol; 1984; 2(1):13-7. PubMed ID: 6088722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of aziridinylbenzoquinone (AZQ) in head and neck cancer.
    Forastiere AA; Crain SM; Callahan K; Van Echo D; Mattox D; Thant M; Von Hoff DD; Wiernik PH
    Cancer Treat Rep; 1982 Dec; 66(12):2097-8. PubMed ID: 6892491
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung.
    Fuks JZ; Aisner J; Van Echo DA; Levitt M; Ihde DC; Carney D; Wiernik PH
    Am J Clin Oncol; 1983 Apr; 6(2):171-3. PubMed ID: 6299094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AZQ therapy in patients with disseminated malignant melanoma.
    Yap BS; Bedikian AY; Burgess MA; Bodey GP
    Am J Clin Oncol; 1982 Dec; 5(6):623-5. PubMed ID: 7165003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and clinical pharmacologic studies of aziridinylbenzoquinone.
    Griffin JP; Newman RA; McCormack JJ; Krakoff IH
    Cancer Treat Rep; 1982 Jun; 66(6):1321-5. PubMed ID: 7083235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical evaluation of AZQ in renal cell carcinoma.
    Decker DA; Kish J; Al-Sarraf M; Goldfarb S
    Am J Clin Oncol; 1986 Apr; 9(2):126-8. PubMed ID: 3717078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.